St. Andrews Health Center

2021

Gram Positive

% Susceptible

** - β-lactamase inhibitors

Gram Positive	# of isolates	PENICILLINS					CEPHALO-SPORIN	GLYCO-PEPTIDE	AMINO-GLYCOSIDE	TETRA-CYCLINE	OXAZOLID-INONE	MACROLIDES		LINCOS-AMIDE	FLUOROQUINOLONES		MISC	URINE ONLY	urine isolates for Fd
		Oxacillin	Ampicillin	Penicillin	Amoxicillin/ K Clavulanate	Ampicillin/ Sulbactam	Cefazolin	Vancomycin	Gentamicin	Tetra cycline	Linezolid	Azithromycin	Erythromycin	Clindamycin	Ciprofloxacin	Levofloxacin	Trimethoprim/ Sulfamethox-azole	Nitrofurantoin	
		Ox	Am	P	Aug **	A/S **	Cfz	Va	Gm	Te	Lzd	Azi	E	Cd	Cp	Lvx	T/S	Fd	
Enterococcus faecalis	29	~	29	~	~	~	~	29	~	6	29	~	~	~	22	23	~	~	25
		~	100.0%	~	~	~	~	100.0%	~	20.7%	100.0%	~	~	~	75.9%	79.3%	~	100.0%	
Enterococcus faecium	1	~	0	~	~	~	~	0	~	0	1	~	~	~	0	0	~	~	1
		~	0.0%	~	~	~	~	0.0%	~	0.0%	100.0%	~	~	~	0.0%	0.0%	~	100.0%	
Strep spp	16	~	~	14	~	~	15	16	~	~	~	9	10	~	~	16	~	~	11
		~	~	87.5%	~	~	93.8%	100.0%	~	~	~	56.3%	62.5%	~	~	100.0%	~	~	
Staph aureus-MSSA	29	29	14	N/A	29	29	~	29	~	29	29	25	24	29	28	28	28	~	2
		100.0%	48.3%		100.0%	100.0%	~	100.0%	~	100.0%	100.0%	86.2%	82.8%	100.0%	96.6%	96.6%	96.6%	100.0%	
Staph aureus-MRSA	16	0	0	N/A	3	6	N/A	16	N/A	16	16	N/A	8	15	7	7	13	~	0
		0.0%	0.0%		18.8%	37.5%		100.0%		100.0%	100.0%		50.0%	93.8%	43.8%	43.8%	81.3%		
Staph aureus - all	45	29	14	N/A	32	35	~	45	~	45	45	50	32	44	35	35	41	~	2
		64.4%	31.1%		71.1%	77.8%	~	100.0%	~	100.0%	100.0%	111.1%	71.1%	97.8%	77.8%	77.8%	91.1%	100.0%	
Staph, coagulase neg	43	28	24	N/A	37	39	~	41	~	39	42	24	23	35	33	33	33	~	11
		65.1%	55.8%		86.0%	90.7%	~	95.3%	~	90.7%	97.7%	55.8%	53.5%	81.4%	76.7%	76.7%	76.7%	100.0%	

~ not reported

N/A N/A, <30% susceptible

Staph aureus Isolates resistant or intermediate to Vancomycin are state reportable.

Staph aureus isolates that test susceptible to Clindamycin will not be reported if isolate is resistant to Erythromycin due to possibility of in-vivo macrolide-induced resistan

% Susceptibility tested with urine isolates only

Do not use without susceptibility results

Strep agalactiae and Strep pyogenes remain universally susceptible to penicillin; for penicillin allergic patients, erythromycin or vancomycin is recommended

This includes Strep spp isolated from urines, wounds or other body sites. Does not include Strep pyogenes isolated from confirmation cultures following rapid strep tests

10-2021 **2021**

Gram Negative

% Susceptible	# of isolates	PENICILLINS				CEPHALOSPORINS					CARBAPENEMS		AMINOGLYCOSIDES		TETRACYCLINE	FLUOROQUINOLONES		OTHER	URINE ONLY	
		Ampicillin	Ampicillin/ Subactam	Amoxicillin/K Clavulanate	Piperacillin/ Tazobacdam	Cefazolin	Cefepime	Ceftazidime	Ceftriaxone	Cefuroxime	Ertapenem	Imipenem	Gentamicin	Tobramycin	Tetracydline	Ciprofloxacin	Levofloxacin	Trimethoprim/ Sulfamethoxazole	Nitrofurantoin	for Fd only
** - β-lactamase inhibitors		Am	A/S **	Aug **	P/T **	Cfz	Cpe	Caz	Cax	Crm	Etp	Imp	Gm	To	Te	Cp	Lvx	T/S	Fd	
E coli	329	238	252	311	324	299	322	324	323	316	329	329	317	311	269	276	274	291		322
		72.3%	76.6%	94.5%	98.5%	90.9%	97.9%	98.5%	98.2%	96.0%	100.0%	100.0%	96.4%	94.5%	81.8%	83.9%	83.3%	88.4%	98.8%	
Citrobacter freundii	16	N/A	N/A	N/A	13	N/A	16	12	10	N/A	16	16	16	16	12	16	16	10		15
					81.3%		100.0%	75.0%	62.5%		100.0%	100.0%	100.0%	100.0%	75.0%	100.0%	100.0%	62.5%	93.3%	
Klebsiella oxytoca	11	N/A	9	10	11	5	11	11	11	10	11	11	11	11	10	11	11	11		9
			81.8%	90.9%	100.0%	45.5%	100.0%	100.0%	100.0%	90.9%	100.0%	100.0%	100.0%	100.0%	90.9%	100.0%	100.0%	100.0%	100.0%	
Klebsiella pneumoniae	35	N/A	29	32	34	31	33	34	33	33	34	34	34	33	30	33	34	33		34
			82.9%	91.4%	97.1%	88.6%	94.3%	97.1%	94.3%	94.3%	97.1%	97.1%	97.1%	94.3%	85.7%	94.3%	97.1%	94.3%	79.4%	
Proteus mirabilis	24	21	24	23	24	21	24	24	24	24	24	21	23	23	N/A	23	23	17	N/A	
		87.5%	100.0%	95.8%	100.0%	87.5%	100.0%	100.0%	100.0%	100.0%	100.0%	87.5%	95.8%	95.8%		95.8%	95.8%	70.8%		
Enterobacter cloacae	18	N/A	N/A	N/A	18	N/A	18	15	12	N/A	18	18	18	18	16	18	17	18		13
					100.0%		100.0%	83.3%	66.7%		100.0%	100.0%	100.0%	100.0%	88.9%	100.0%	94.4%	100.0%	23.1%	
Enterobacter aerogenes	6	N/A	N/A	N/A	5	N/A	6	5	5	N/A	6	6	5	5	5	6	6	6		6
					83.3%		100.0%	83.3%	83.3%		100.0%	100.0%	83.3%	83.3%	83.3%	100.0%	100.0%	100.0%	66.7%	
Pseudomonas aeruginosa	20	0	1	3	17	0	17	17	6	0	8	20	17	19	1	19	19	2		19
		0.0%	5.0%	15.0%	85.0%	0.0%	85.0%	85.0%	30.0%	0.0%	40.0%	100.0%	85.0%	95.0%	5.0%	95.0%	95.0%	10.0%	0.0%	

N/A N/A, <30% susceptible

Drugs considered for Carbapenem-resistant enterobacteriaciae (CRE) and Imipenem-resistant Pseudomonas (IRPA) (State reportable isolates)

% Susceptibility tested with urine isolates only